How AI Continues To Drive MedTech M&A
Capital continues to flow into MedTech M&A as companies pursue AI-driven solutions to streamline administrative tasks and drive improved patient outcomes.
In a recent interview with Citeline for the article “Industry Experts Expect AI-Driven MedTech M&A to Continue in 2025,” PMCF Investment Banking Managing Director Bryan Hughes highlighted the continued shift.
Hughes, who leads the firm’s Healthcare and MedTech verticals, said both strategic buyers and private equity investors are looking toward platforms that can integrate AI and deliver measurable value. This value is driven by scalable platforms that can be implemented, often for larger strategics or investors, he said.
“Typically, those companies don’t have the resources internally” to create and implement their own holistic solutions to drive better outcomes, Hughes told Citeline.
Recently, Hughes and PMCF Vice President Mike Brooks authored “How Artificial Intelligence is Rewriting the Playbook for Healthcare M&A,” including insights on MedTech, clinical, administrative, and analytics.
“Sellers with integrated AI-solutions have commanded aggressive valuations, with buyers seeking high-growth, capital-efficient companies,” Hughes and Brooks wrote.
To read the Citeline article (subscription required), click here
To read “How Artificial Intelligence is Rewriting the Playbook for Healthcare M&A,” click here
More Articles
Distributors See Improving M&A Opportunity In 2026
After a year defined by uneven activity and macro uncertainty, M&A momentum enters 2026 with improving financing conditions, renewed buyer confidence, and substantial capital on the sidelines, creating a more constructive environment for well-positioned middle-market distributors.
HCM M&A Outlook 2026: AI, Specialization, and Global Shifts Shape Deal Flow
After years of volatility and transformation, the Human Capital Management (HCM) industry now finds itself navigating a landscape where geopolitical tensions and technological acceleration collide to create both unique challenges and new frontiers for growth.
Continued Momentum Drives Optimistic 2026 Plastics M&A Outlook
From transaction volume to EBITDA multiples, key indicators for plastics M&A are trending upward as 2026 begins, according to PMCF Investment Banking Managing Director John Hart.
The Long-Term Perspective: Insights from PMCF’s 30 Years in Middle-Market M&A
Thirty years ago, PMCF Investment Banking set out with a clear mission: to redefine how middle‑market businesses approach M&A.
2026 Medtech M&A Outlook Strengthens as Buyers Prioritize Innovation and Resilience
Medtech is entering 2026 with a healthier M&A environment supported by improved financing conditions, resilient sector performance, and a more straightforward path for strategic buyers and private equity.